Cargando…

Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors

Cocaine addiction is a widespread psychiatric condition still waiting for approved efficacious medications. Previous studies suggested that simultaneous activation of nociceptin opioid (NOP) and mu opioid (MOP) receptors could be a successful strategy to treat cocaine addiction, but the paucity of m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Qianwei, Deng, Yulin, Ciccocioppo, Roberto, Cannella, Nazzareno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693905/ https://www.ncbi.nlm.nih.gov/pubmed/29180970 http://dx.doi.org/10.3389/fpsyt.2017.00234

Ejemplares similares

Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist
por: Rizzi, Anna, et al.
Publicado: (2016)

NOP Receptor Agonist Ro 64-6198 Decreases Escalation of Cocaine Self-Administration in Rats Genetically Selected for Alcohol Preference
por: Li, Hongwu, et al.
Publicado: (2019)

Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain
por: Sałat, Kinga, et al.
Publicado: (2017)

Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model
por: Christoph, Thomas, et al.
Publicado: (2018)

Cebranopadol: A First-in-Class Nociceptin Receptor Agonist for Managing Chronic Pain
por: Nair, Abhijit S, et al.
Publicado: (2020)

Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists
por: Park, Jong Yung, et al.
Publicado: (2019)

Network-Based Discovery of Opioid Use Vulnerability in Rats Using the Bayesian Stochastic Block Model
por: Allen, Carter, et al.
Publicado: (2021)

Discovery of the First Small-Molecule Opioid Pan Antagonist with Nanomolar Affinity at Mu, Delta, Kappa, and Nociceptin Opioid Receptors
por: Zaveri, Nurulain T., et al.
Publicado: (2015)

Interactions Between Opioids and Dextroamphetamine on Locomotor Activity: Influence of an Opioid's Relative Efficacy at the Mu Receptor
por: Smith, Mark A., et al.
Publicado: (2022)

Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships
por: Journigan, V. Blair, et al.
Publicado: (2017)

Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity
por: Greedy, Benjamin M., et al.
Publicado: (2013)

Prevalence of Opioid Dependence and Opioid Agonist Treatment in the Berlin Custodial Setting: A Cross-Sectional Study
por: von Bernuth, Kira, et al.
Publicado: (2020)

Ligand-Specific Regulation of the Endogenous Mu-Opioid Receptor by Chronic Treatment with Mu-Opioid Peptide Agonists
por: Murányi, Marianna, et al.
Publicado: (2013)

Selectively Promiscuous Opioid Ligands: Discovery of High Affinity/Low Efficacy Opioid Ligands with Substantial Nociceptin Opioid Peptide Receptor Affinity
por: Kumar, Vinod, et al.
Publicado: (2014)

The Nociceptin Receptor (NOP) Agonist AT-312 Blocks Acquisition of Morphine- and Cocaine-Induced Conditioned Place Preference in Mice
por: Zaveri, Nurulain T., et al.
Publicado: (2018)

Bifunctional peptide-based opioid agonist/nociceptin antagonist ligand for dual treatment of nociceptive and neuropathic pain
por: Lagard, Camille, et al.
Publicado: (2016)

Opioid-Modulated Receptor Localization and Erk1/2 Phosphorylation in Cells Coexpressing μ-Opioid and Nociceptin Receptors
por: Zhuo, Guan-Yu, et al.
Publicado: (2023)

Association of prescribed oral stimulants on cocaine use among patients enrolled in opioid agonist treatment: A retrospective longitudinal cohort study
por: Tatangelo, Mark, et al.
Publicado: (2022)

Effects of Cebranopadol on Cocaine-induced Hyperactivity and Cocaine Pharmacokinetics in Rats
por: Wei, Huimei, et al.
Publicado: (2020)

Heterodimerization of Mu Opioid Receptor Protomer with Dopamine D(2) Receptor Modulates Agonist-Induced Internalization of Mu Opioid Receptor
por: Vasudevan, Lakshmi, et al.
Publicado: (2019)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
por: Soyka, Michael
Publicado: (2021)

Microglia Express Mu Opioid Receptor: Insights From Transcriptomics and Fluorescent Reporter Mice
por: Maduna, Tando, et al.
Publicado: (2019)

Dopamine Supersensitivity: A Novel Hypothesis of Opioid-Induced Neurobiological Mechanisms Underlying Opioid-Stimulant Co-use and Opioid Relapse
por: Strickland, Justin C., et al.
Publicado: (2022)

Effects of Co-Administration of Intrathecal Nociceptin/Orphanin FQ and Opioid Antagonists on Formalin-Induced Pain in Rats
por: Lee, Heeseung
Publicado: (2013)

Kappa-Opioid Receptor Signaling in the Striatum as a Potential Modulator of Dopamine Transmission in Cocaine Dependence
por: Trifilieff, Pierre, et al.
Publicado: (2013)

Chronic Pain Opioid-Maintained Patients Receive Less Analgesic Opioid Prescriptions
por: Delorme, Jessica, et al.
Publicado: (2018)

Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders
por: Burns, Jamie A., et al.
Publicado: (2019)

Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment
por: Specka, Michael, et al.
Publicado: (2022)

The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons—Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids
por: Buadze, Anna, et al.
Publicado: (2020)

Role of Mu and Delta Opioid Receptors in the Nucleus Accumbens in Cocaine-Seeking Behavior
por: Simmons, Diana, et al.
Publicado: (2009)

Chronic tianeptine induces tolerance in analgesia and hyperlocomotion via mu-opioid receptor activation in mice
por: Allain, Florence, et al.
Publicado: (2023)

Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study
por: Göhler, Karin, et al.
Publicado: (2019)

In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential
por: Khroyan, Taline V., et al.
Publicado: (2017)

[18F]-Fluorodeoxyglucose-Positron Emission Tomography in Rats with Prolonged Cocaine Self-Administration Suggests Potential Brain Biomarkers for Addictive Behavior
por: Cannella, Nazzareno, et al.
Publicado: (2017)

Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors
por: Cueva, Juan Pablo, et al.
Publicado: (2015)

Availability of opioid agonist treatment and critical incidents in Forensic Clinics for Dependency Diseases in Germany
por: Reiners, Sven, et al.
Publicado: (2022)

CB1 Agonism Alters Addiction-Related Behaviors in Mice Lacking Mu or Delta Opioid Receptors
por: Roeckel, Laurie-Anne, et al.
Publicado: (2018)

Mechanistic Characterization of the Pharmacological Profile of HS-731, a Peripherally Acting Opioid Analgesic, at the µ-, δ-, κ-Opioid and Nociceptin Receptors
por: Puls, Kristina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_83d1mobpt2k9bfdlevoqee5lof